Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

TB-500 Versus Standard Recovery Interventions

TB-500 (2.0mg 2×/week loading) Satellite cell activation, actin polymerisation, VEGF upregulation 30–50% for Grade I–II tears High. 3–4× VEGF increase, sustained angiogenesis Moderate. Supports remodelling phase indirectly Preclinical (rodent models) + observa

This comparison does not assign a generated winner or score.

  • TB-500 (2.0mg 2×/week loading)
  • Satellite cell activation, actin polymerisation, VEGF upregulation
  • 30–50% for Grade I–II tears
  • High. 3–4× VEGF increase, sustained angiogenesis
  • Moderate. Supports remodelling phase indirectly
  • Preclinical (rodent models) + observational case reports
  • BPC-157 (250–500mcg daily)
  • Growth hormone receptor modulation, fibroblast activation
  • 20–40% for soft tissue injuries
  • Moderate. Promotes angiogenesis via different pathway
  • Low. Primarily early-phase repair
  • Preclinical (rodent models)
  • Platelet-Rich Plasma (PRP) injection
  • Growth factor delivery (PDGF, TGF-β, IGF-1) from concentrated platelets
  • 15–30% (highly variable by preparation method)
  • Moderate. Transient growth factor spike
  • Moderate. Depends on injection timing
  • Mixed. Some RCTs show benefit, others show no effect vs placebo
  • NSAIDs (ibuprofen, naproxen)
  • COX enzyme inhibition, prostaglandin suppression
  • None. May delay healing by 10–20%
  • Low. Suppresses angiogenesis signalling
  • None. May impair collagen synthesis
  • Strong evidence for pain relief; emerging evidence suggests delayed healing
  • Corticosteroid injection
  • Glucocorticoid receptor activation, broad immune suppression
  • None. Accelerates pain relief but weakens healed tissue
  • Low. Suppresses VEGF and angiogenesis
  • Negative. Reduces collagen cross-linking and tensile strength
  • Strong evidence for short-term pain control; consistent evidence of long-term tissue weakening
  • The bottom line: TB-500's mechanism targets tissue regeneration, not symptom management. NSAIDs and corticosteroids reduce pain quickly but suppress the biological processes required for full structural repair. Creating a tradeoff between immediate comfort and long-term tissue integrity.
More references

Related material